Insmed Incorporated

Equities

INSM

US4576693075

Market Closed - Nasdaq Other stock markets 01:30:00 11/04/2026 am IST			5-day change	1st Jan Change
154.81 ^USD	-3.00%		-5.49%	-11.05%

09/04	Insmed Insider Sold Shares Worth $1,746,336, According to a Recent SEC Filing	MT
08/04	Mizuho Trims Price Target on Insmed to $202 From $206, Keeps Outperform Rating	MT

Transcript : Insmed Incorporated Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09

Published on 03/02/2026 at 09:20 pm IST - Modified on 03/02/2026 at 10:35 pm IST

S&P Capital IQ

Presenter Speech
Ritu Baral (Analysts)

Here we go. All right. Welcome, everyone, to the Insmed fireside chat at the TD Cowen Healthcare Conference. I am covering analyst, Ritu Baral. And with me from

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Insmed Incorporated

09/04	Insmed Insider Sold Shares Worth $1,746,336, According to a Recent SEC Filing	MT
08/04	Mizuho Trims Price Target on Insmed to $202 From $206, Keeps Outperform Rating	MT
08/04	Insmed to End Hidradenitis Suppurativa Program After Study Fails	MT
08/04	Insmed discontinues development of skin condition drug after mid-stage study miss	RE
08/04	Insmed discontinues development of skin condition drug	RE
08/04	Insmed Incorporated Provides Clinical Update on Phase 2b CEDAR Study	CI
07/04	RBC Capital Adjusts Price Target on Insmed to $212 From $203, Maintains Outperform Rating	MT
31/03	UBS Adjusts Price Target on Insmed to $185 From $215, Maintains Buy Rating	MT
31/03	US Equity Markets Mixed After Federal Reserve Chair Powell's Reassuring Comments on Inflation	MT
30/03	Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says	MT
30/03	Bad News Is Bad News Again
30/03	Morgan Stanley Upgrades Insmed to Overweight From Equalweight, Raises Price Target to $212 From $166	MT
30/03	Analyst recommendations: AMD, Expedia, Instacart, Coinbase, Elf beauty…
24/03	Mizuho Lifts Price Target on Insmed to $206 From $204, Keeps Outperform Rating	MT
24/03	Insmed Shares Climb on Positive Results for Arikayce